Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease

Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood‐based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, sever...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alzheimer's & dementia 2024-11, Vol.20 (11), p.8209-8215
Hauptverfasser:	Mielke, Michelle M., Anderson, Matthew, Ashford, J. Wesson, Jeromin, Andreas, Lin, Pei‐Jung, Rosen, Allyson, Tyrone, Jamie, VandeVrede, Lawren, Willis, Deanna, Hansson, Oskar, Khachaturian, Ara S., Schindler, Suzanne E., Weiss, Joan, Batrla, Richard, Bozeat, Sasha, Dwyer, John R., Holzapfel, Drew, Jones, Daryl Rhys, Murray, James F., Partrick, Katherine A., Scholler, Emily, Vradenburg, George, Young, Dylan, Braunstein, Joel B., Burnham, Samantha C., Oliveira, Fabricio Ferreira, Hu, Yan Helen, Mattke, Soeren, Merali, Zul, Monane, Mark, Sabbagh, Marwan Noel, Shobin, Eli, Weiner, Michael W., Udeh‐Momoh, Chinedu T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - blood Alzheimer Disease - diagnosis Alzheimer's disease amyloid Basic Medicine biomarker Biomarkers - blood blood-based biomarkers clinical implementation clinical practice cognitive impairment disease-modifying treatment Early Diagnosis ethics Humans Medical and Health Sciences Medicin och hälsovetenskap Medicinska och farmaceutiska grundvetenskaper Neurosciences Neurovetenskaper patient journey Policy Forum primary care secondary care United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!